Clinical trial
Amphotericin B Suspension in Refractory Chronic Sinusitis
NCT00425620 · Accentia Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00425620 |
|---|---|
| Title | Amphotericin B Suspension in Refractory Chronic Sinusitis |
| Official title | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Intranasal Amphotericin B Suspension in Patients With Refractory, Postsurgical Chronic Sinusitis (CS) |
| Lead sponsor | Accentia Biopharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Sinusitis |
| Intervention type | Drug |
| Interventions | SinuNase |
| Enrollment | 300 |
| Start date | Dec 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Jan 23, 2007 |
| Last update posted | Nov 30, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: